Hexter Joshua 4

What Happened

• Joshua Hexter, Oramed Pharmaceuticals’ Chief Operating Officer and Chief Business Officer, received 19,000 shares of ORMP common stock on January 22, 2026 upon vesting of performance stock units (PSUs). The shares were issued for no consideration (19,000 @ $0.00). The Form 4 reports the derivative conversion/vesting under code M.

Key Details

• Transaction date: 2026-01-22 (reported on Form 4 filed 2026-01-29).
• Shares received: 19,000 shares; price paid: $0.00 (issued upon vesting).
• Transaction type/code: Vesting/conversion of PSUs reported as M (exercise/conversion of derivative).
• Footnotes: PSUs were granted 12/31/2025 and vested 1/22/2026 after the company’s stock hit a specified price; each PSU converted into one share.
• Shares owned after transaction: Not specified in the filing.
• Timeliness: Form 4 was filed 7 days after the transaction date (appears late relative to the usual 2-business-day filing requirement).

Context

• This was an award vesting (performance-based PSU settlement), not an open-market purchase or a sale. The filing shows conversion of contingent performance units into shares; no immediate sale of the newly issued shares is reported on this Form 4. Awards like this reflect compensation tied to performance targets and do not, by themselves, indicate insider buying or selling intent.